Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 7/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | RARA | P10276 | 1/20 | 0.34 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
| ▸ | RARG | P13631 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.34 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.34 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12876170 | 0.88 | RARA (0.39) | POLBHTR2CKLKB1RARARARB | |
| SCHEMBL12876089 | 0.88 | L3MBTL1 (0.41) | L3MBTL1POLBTDP1HSD17B10KLKB1 | |
| SCHEMBL1198155 | 0.88 | EIF4E (0.38) | L3MBTL1POLBTDP1HSD17B10KLKB1 | |
| SCHEMBL1197772 | 0.81 | MPL (0.40) | L3MBTL1KLKB1 | |
| SCHEMBL30617732 | 0.81 | MPL (0.40) | L3MBTL1KLKB1 | |
| SCHEMBL12876184 | 0.80 | KCNH2 (0.43) | L3MBTL1POLBTDP1HSD17B10KLKB1 | |
| SCHEMBL1198409 | 0.80 | L3MBTL1 (0.37) | L3MBTL1POLBTDP1KLKB1RARA | |
| SCHEMBL12875936 | 0.79 | RARA (0.43) | L3MBTL1POLBTDP1KLKB1RARA | |
| SCHEMBL1198824 | 0.77 | GRM2 (0.38) | L3MBTL1POLBKLKB1RARARARB | |
| SCHEMBL12876075 | 0.77 | GRM2 (0.42) | HSD17B10KLKB1RARARARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461348-B2 | Heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | PDE3B, PDE5A, PDE2A | L3MBTL1 4726/4885POLB 4137/4885TDP1 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.